Molecular targeted therapy of glioblastoma.

[1]  R. Stupp,et al.  Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis , 2020, International journal of cancer.

[2]  K. Tamura,et al.  Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts , 2019, Cancer science.

[3]  A. Hauschild,et al.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. , 2019, The New England journal of medicine.

[4]  Sankha S. Basu,et al.  Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Gilbert,et al.  MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials , 2018, Clinical Cancer Research.

[6]  P. Wen,et al.  RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) , 2018, Neuro-Oncology.

[7]  David M. Hyman,et al.  BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  David T. W. Jones,et al.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. , 2018, Neuro-oncology.

[9]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[10]  David T. W. Jones,et al.  Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis , 2018, Brain pathology.

[11]  Jennie W. Taylor,et al.  Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma , 2018, Journal of Neuro-Oncology.

[12]  L. Held,et al.  Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Weller,et al.  Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). , 2018 .

[14]  R. McLendon,et al.  A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma , 2018, Clinical Cancer Research.

[15]  J. Huse,et al.  Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas , 2018, Journal of neuropathology and experimental neurology.

[16]  Albert Lai,et al.  Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. , 2018, International journal of radiation oncology, biology, physics.

[17]  P. Wen,et al.  Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma , 2018, Cancer.

[18]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[19]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[20]  Martin Klein,et al.  Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.

[21]  T. Mikkelsen,et al.  Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy , 2017, Neuro-oncology.

[22]  Act Investigators.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .

[23]  G. Reifenberger,et al.  Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors , 2017, Clinical Cancer Research.

[24]  T. Mikkelsen,et al.  Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy , 2017, Neuro-oncology.

[25]  Brian M Alexander,et al.  Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE , 2017, Clinical Cancer Research.

[26]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[27]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[28]  A. Brandes,et al.  OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 , 2017 .

[29]  L. Recht,et al.  Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Roland Eils,et al.  Recurrent MET fusion genes represent a drug target in pediatric glioblastoma , 2016, Nature Medicine.

[31]  H. Urbach,et al.  Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Brandes,et al.  AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. , 2016, Neuro-oncology.

[34]  A. Brandes,et al.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.

[35]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[36]  R. Stupp,et al.  Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082) , 2016, Clinical Cancer Research.

[37]  M. Weller,et al.  Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo , 2016, Neuro-oncology.

[38]  G. Fuller,et al.  PD-L1 expression and prognostic impact in glioblastoma. , 2016, Neuro-oncology.

[39]  M. Gilbert,et al.  Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Idbaih,et al.  Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. , 2015, CNS oncology.

[41]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[42]  J. Sarkaria,et al.  A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. , 2015, Neuro-oncology.

[43]  M. Weller,et al.  Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.

[44]  K. Camphausen,et al.  A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. , 2015, International journal of radiation oncology, biology, physics.

[45]  M. J. van den Bent,et al.  Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. , 2015, Neuro-oncology.

[46]  R. Bourgon,et al.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  T. Mikkelsen,et al.  Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. , 2015, Neuro-oncology.

[48]  Katrina H. Smith,et al.  A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients , 2015, Clinical Cancer Research.

[49]  M. Weller,et al.  Transforming growth factor-β pathway activity in glioblastoma , 2015, Oncotarget.

[50]  G. Reifenberger,et al.  MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial , 2015, Clinical Cancer Research.

[51]  A. Iavarone,et al.  Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.

[52]  J. Pichler,et al.  A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma , 2014, Clinical Cancer Research.

[53]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[54]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[55]  Sabine Tejpar,et al.  European perspective for effective cancer drug development , 2014, Nature Reviews Clinical Oncology.

[56]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[57]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[58]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[59]  A. von Deimling,et al.  Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. , 2013, Neuro-oncology.

[60]  T. Mikkelsen,et al.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  D. Aisner,et al.  Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation , 2013, The American journal of surgical pathology.

[62]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[63]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[64]  M. Weller,et al.  Integrin control of the transforming growth factor-β pathway in glioblastoma. , 2013, Brain : a journal of neurology.

[65]  M. Hegi,et al.  A safety run‐in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) , 2012, Cancer.

[66]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[67]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[68]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[69]  Caterina Giannini,et al.  Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. , 2012, Neuro-oncology.

[70]  Jeffrey W. Clark,et al.  Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Mirimanoff,et al.  Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma , 2011, Neurology.

[72]  Susan M. Chang,et al.  Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Martin Glas,et al.  c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype , 2011, Proceedings of the National Academy of Sciences.

[74]  M. Delorenzi,et al.  Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial , 2011, Molecular Cancer Therapeutics.

[75]  P. Wen,et al.  A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. , 2011, Neuro-oncology.

[76]  M. Zaaroor,et al.  Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study , 2010, Neuro-oncology.

[77]  S. Konduri,et al.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. , 2010, Neuro-oncology.

[78]  Thomas Benner,et al.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Alessia Pica,et al.  Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  H. Fine,et al.  Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas , 2010, Cancer.

[81]  W. Mason,et al.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  T. Mikkelsen,et al.  Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Susan M. Chang,et al.  Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 , 2005, Clinical Cancer Research.

[88]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[89]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[90]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[91]  K. Plate,et al.  Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible In vivo regulatory mechanisms , 1994, International journal of cancer.

[92]  A. Brandes,et al.  Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. , 2019, The Lancet. Oncology.

[93]  Eilon D. Kirson,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma , 2017 .

[94]  S. Paek,et al.  C-MET overexpression and amplification in gliomas. , 2015, International journal of clinical and experimental pathology.

[95]  G. Sundar,et al.  Glioma , 2015, Nature Reviews Disease Primers.